TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incorporating PROMIS Symptom Measures Into Primary Care Practice
Brief Summary: The purpose of this study is to determine the effectiveness of providing PROMIS Profile Scale scores (e.g., sleep, pain, anxiety, depression, energy/fatigue) to physicians on patients' symptoms.


Options:
A: Arm Label: FLARE Intervention Group; Type: OTHER; Interventions: Other: FLARE Intervention Group | Arm Label: Standard of Care (SOC) Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: FLARE Intervention Group; Assigned to Arm(s): FLARE Intervention Group
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Questioners | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: STAR website | Intervention Type: BEHAVIORAL; Name: Questioners; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: STAR website; Assigned to Arm(s): B
C: Arm Label: Feedback Group; Type: EXPERIMENTAL; Interventions: Other: Feedback Group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Feedback Group; Assigned to Arm(s): Feedback Group
D: Arm Label: Personal counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Personal Counseling | Arm Label: Computer generated feedback letters; Type: EXPERIMENTAL; Interventions: Behavioral: Computer-generated feedback letters | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Personal Counseling; Assigned to Arm(s): Personal counseling | Intervention Type: BEHAVIORAL; Name: Computer-generated feedback letters; Assigned to Arm(s): Computer generated feedback letters

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder
Brief Summary: This study is a control trial of sertraline (Zoloft) in children aged 2 to 5 years old inclusive with Autism Spectrum Disorder. The trial is six months long, and each participant will receive a series of tests at both the beginning and end of the study. The researchers hope to show improvements in language and social deficits.


Options:
A: Arm Label: Transdermal nicotine first, placebo last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Arm Label: Transdermal placebo first, nicotine last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Intervention Type: DRUG; Name: Transdermal nicotine; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last | Intervention Type: OTHER; Name: Transdermal placebo; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last
B: Arm Label: DB Placebo Nasal Spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double blind phase Placebo Nasal Spray | Arm Label: DB Oxytocin Nasal Spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: double Blind Oxytocin Nasal Spray | Arm Label: open label intranasal oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open Label intranasal oxytocin | Intervention Type: DRUG; Name: Double blind phase Placebo Nasal Spray; Assigned to Arm(s): DB Placebo Nasal Spray | Intervention Type: DRUG; Name: double Blind Oxytocin Nasal Spray; Assigned to Arm(s): DB Oxytocin Nasal Spray | Intervention Type: DRUG; Name: Open Label intranasal oxytocin; Assigned to Arm(s): open label intranasal oxytocin
C: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Sertraline Liquid Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sertraline Liquid Placebo | Arm Label: Sertraline Active Medication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Intervention Type: DRUG; Name: Sertraline Liquid Placebo; Assigned to Arm(s): Sertraline Liquid Placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Sertraline Active Medication

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bimodal Pre-habilitation Program to Improve Symptom Control After Treatment for Head and Neck Cancer
Brief Summary: The purpose of this study is to explore whether early initiated physical exercise concurrent with a swallowing and mouth opening exercise program will have a positive effect on swallowing function and other quality of life aspects in patients treated with radiotherapy for head and neck cancer. The investigators hypothesize that patients who complete the program will have improved swallowing function and physical function one year after completing their treatment compared to patients who do not participate in the training program.


Options:
A: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical exercise, Other: best supportive care | Arm Label: No exercise; Type: OTHER; Interventions: Other: best supportive care | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): Exercise | Intervention Type: OTHER; Name: best supportive care; Assigned to Arm(s): Exercise, No exercise
B: Arm Label: Swallowing therapy & resistance training; Type: EXPERIMENTAL; Interventions: Behavioral: Swallowing therapy & resistance training | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Swallowing therapy & resistance training; Assigned to Arm(s): Swallowing therapy & resistance training
C: Arm Label: Training Group; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Training Group
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Three Different Prophylactic Treatments of Postoperative Nausea and Vomiting in Patients Undergoing Vitrectomy Under Local Anesthesia
Brief Summary: Vitreoretinal surgery is associated with a considerable incidence of postoperative nausea and vomiting (PONV), which is reported to be as high as 60%. Reasons for this high incidence may be the long duration of surgery and anesthesia and the high degree of manipulation of the eye. Postoperative vomiting after vitrectomy is an important risk factor for the onset of several complications, such as suprachoroidal hemorrhage, with disastrous visual consequences.

To date there is no evidence as to the possible protective effect of anti-emetic therapy with regard to interventions of vitrectomy performed under local anesthesia.

In this prospective, randomized, multicenter, double blind study, we evaluated the efficacy of Ondansetron alone, Dexamethasone alone and in combination in controlling nausea and vomiting in patients undergoing vitrectomy under local anesthesia.


Options:
A: Arm Label: Ondansetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ondansetron | Arm Label: Granisetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Granisetron | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Ondansetron | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): Granisetron
B: Intervention Type: DRUG; Name: MK0869, aprepitant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: ondansetron IV; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo
D: Arm Label: PLACEBO Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO | Arm Label: DEXAMETHASONE Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: ONDANSETRON; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ondansetron | Arm Label: DEXAMETHASONE + ONDANSETRON; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone + Ondansetron | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): PLACEBO Group | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DEXAMETHASONE Group | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): ONDANSETRON | Intervention Type: DRUG; Name: Dexamethasone + Ondansetron; Assigned to Arm(s): DEXAMETHASONE + ONDANSETRON

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Brief Summary: The primary objective of the study is to examine the efficacy of multiple doses of Nusinersen administered intrathecally in preventing or delaying the need for respiratory intervention or death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA). Secondary objectives of this study are to examine the effects of Nusinersen in infants with genetically diagnosed and presymptomatic SMA.


Options:
A: Arm Label: nusinersen; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): nusinersen | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure
B: Arm Label: Nusinersen; Type: EXPERIMENTAL; Interventions: Drug: Nusinersen | Intervention Type: DRUG; Name: Nusinersen; Assigned to Arm(s): Nusinersen
C: N/A
D: Intervention Type: DRUG; Name: Valproic Acid; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Brief Summary: The primary objective of the study is to examine the efficacy of multiple doses of Nusinersen administered intrathecally in preventing or delaying the need for respiratory intervention or death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA). Secondary objectives of this study are to examine the effects of Nusinersen in infants with genetically diagnosed and presymptomatic SMA.


Options:
A: Intervention Type: DRUG; Name: Valproic Acid; Assigned to Arm(s): N/A
B: Arm Label: Nusinersen; Type: EXPERIMENTAL; Interventions: Drug: Nusinersen | Intervention Type: DRUG; Name: Nusinersen; Assigned to Arm(s): Nusinersen
C: Arm Label: Cohort 1a; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine, Drug: Placebo | Arm Label: Cohort 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Valproic Acid and Levocarnitine | Intervention Type: DRUG; Name: Valproic Acid and Levocarnitine; Assigned to Arm(s): Cohort 1a, Cohort 1b, Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1a
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Intervention Type: BIOLOGICAL; Name: AVXS-101; Assigned to Arm(s): Cohort 1, Cohort 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dialectical Behaviour Therapy for Chronically Self-harming Individuals With BPD: Evaluating the Clinical and Cost Effectiveness of a 6-month Treatment
Brief Summary: Standard one-year dialectical behaviour therapy (DBT), which has four components, is an effective treatment for people with borderline personality disorder. However, such DBT programs are in short supply and costly, resulting in long wait lists. In practice, DBT is often reduced in length or intensity. This study will determine whether shorter DBT treatment is clinically effective and cost-effective. In total, 240 self-harming BPD patients will be randomly assigned to receive either 1 year or 6 months of DBT, with follow-up lasting two years. Rates of suicidal and self-harm behaviours, use of health care and general psychological functioning will be examined.


Options:
A: Arm Label: Dialectical Behaviour Therapy-6 months; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy-6 months | Arm Label: Dialectical Behaviour Therapy-12 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behaviour Therapy-12 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-6 months; Assigned to Arm(s): Dialectical Behaviour Therapy-6 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-12 months; Assigned to Arm(s): Dialectical Behaviour Therapy-12 months
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: PTSD-EMDR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: EMDR | Arm Label: Integrated DBT-EMDR; Type: EXPERIMENTAL; Interventions: Behavioral: EMDR, Behavioral: DBT | Intervention Type: BEHAVIORAL; Name: EMDR; Assigned to Arm(s): Integrated DBT-EMDR, PTSD-EMDR | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Integrated DBT-EMDR
D: Arm Label: therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioural therapy | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive behavioural therapy; Assigned to Arm(s): therapy | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dialectical Behaviour Therapy for Chronically Self-harming Individuals With BPD: Evaluating the Clinical and Cost Effectiveness of a 6-month Treatment
Brief Summary: Standard one-year dialectical behaviour therapy (DBT), which has four components, is an effective treatment for people with borderline personality disorder. However, such DBT programs are in short supply and costly, resulting in long wait lists. In practice, DBT is often reduced in length or intensity. This study will determine whether shorter DBT treatment is clinically effective and cost-effective. In total, 240 self-harming BPD patients will be randomly assigned to receive either 1 year or 6 months of DBT, with follow-up lasting two years. Rates of suicidal and self-harm behaviours, use of health care and general psychological functioning will be examined.


Options:
A: Arm Label: Dialectical Behaviour Therapy-6 months; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy-6 months | Arm Label: Dialectical Behaviour Therapy-12 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behaviour Therapy-12 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-6 months; Assigned to Arm(s): Dialectical Behaviour Therapy-6 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-12 months; Assigned to Arm(s): Dialectical Behaviour Therapy-12 months
B: Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS
C: Arm Label: MBT therapy plus treatment as usual; Type: EXPERIMENTAL; Interventions: Other: Mentalization-Based Group Therapy for Adolescents | Arm Label: Treatment as usual alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mentalization-Based Group Therapy for Adolescents; Assigned to Arm(s): MBT therapy plus treatment as usual
D: Arm Label: Mentalization Based Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Mentalization Based Treatment | Arm Label: Treatment As Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment As Usual | Intervention Type: BEHAVIORAL; Name: Mentalization Based Treatment; Assigned to Arm(s): Mentalization Based Treatment | Intervention Type: BEHAVIORAL; Name: Treatment As Usual; Assigned to Arm(s): Treatment As Usual

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dialectical Behaviour Therapy for Chronically Self-harming Individuals With BPD: Evaluating the Clinical and Cost Effectiveness of a 6-month Treatment
Brief Summary: Standard one-year dialectical behaviour therapy (DBT), which has four components, is an effective treatment for people with borderline personality disorder. However, such DBT programs are in short supply and costly, resulting in long wait lists. In practice, DBT is often reduced in length or intensity. This study will determine whether shorter DBT treatment is clinically effective and cost-effective. In total, 240 self-harming BPD patients will be randomly assigned to receive either 1 year or 6 months of DBT, with follow-up lasting two years. Rates of suicidal and self-harm behaviours, use of health care and general psychological functioning will be examined.


Options:
A: Arm Label: Brief Admission; Type: EXPERIMENTAL; Interventions: Other: Brief Admission | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Brief Admission; Assigned to Arm(s): Brief Admission
B: Arm Label: Mindfulness condition; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness | Arm Label: Control condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Mindfulness condition
C: Arm Label: Dialectical Behaviour Therapy-6 months; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy-6 months | Arm Label: Dialectical Behaviour Therapy-12 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behaviour Therapy-12 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-6 months; Assigned to Arm(s): Dialectical Behaviour Therapy-6 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-12 months; Assigned to Arm(s): Dialectical Behaviour Therapy-12 months
D: Arm Label: CHESS Mobile Health Group; Type: EXPERIMENTAL; Interventions: Device: CHESS Mobile Health smart phone application, Behavioral: Problem solving therapy | Intervention Type: DEVICE; Name: CHESS Mobile Health smart phone application; Assigned to Arm(s): CHESS Mobile Health Group | Intervention Type: BEHAVIORAL; Name: Problem solving therapy; Assigned to Arm(s): CHESS Mobile Health Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dialectical Behaviour Therapy for Chronically Self-harming Individuals With BPD: Evaluating the Clinical and Cost Effectiveness of a 6-month Treatment
Brief Summary: Standard one-year dialectical behaviour therapy (DBT), which has four components, is an effective treatment for people with borderline personality disorder. However, such DBT programs are in short supply and costly, resulting in long wait lists. In practice, DBT is often reduced in length or intensity. This study will determine whether shorter DBT treatment is clinically effective and cost-effective. In total, 240 self-harming BPD patients will be randomly assigned to receive either 1 year or 6 months of DBT, with follow-up lasting two years. Rates of suicidal and self-harm behaviours, use of health care and general psychological functioning will be examined.


Options:
A: Arm Label: Iconic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Emotional regulation | Arm Label: Support therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Emotional regulation | Intervention Type: BEHAVIORAL; Name: Emotional regulation; Assigned to Arm(s): Iconic Therapy, Support therapy
B: Arm Label: MYPLAN app; Type: EXPERIMENTAL; Interventions: Other: MYPLAN-safety plan as an application for smart phones | Arm Label: Safety plan on paper; Type: ACTIVE_COMPARATOR; Interventions: Other: safety plan on paper | Intervention Type: OTHER; Name: MYPLAN-safety plan as an application for smart phones; Assigned to Arm(s): MYPLAN app | Intervention Type: OTHER; Name: safety plan on paper; Assigned to Arm(s): Safety plan on paper
C: Arm Label: Dialectical Behaviour Therapy-6 months; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy-6 months | Arm Label: Dialectical Behaviour Therapy-12 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behaviour Therapy-12 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-6 months; Assigned to Arm(s): Dialectical Behaviour Therapy-6 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-12 months; Assigned to Arm(s): Dialectical Behaviour Therapy-12 months
D: Arm Label: Dialectical behavior therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavior therapy (DBT) | Arm Label: alternative psychotherapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical behavior therapy (DBT) | Intervention Type: BEHAVIORAL; Name: Dialectical behavior therapy (DBT); Assigned to Arm(s): Dialectical behavior therapy, alternative psychotherapy

Answer: C